Diroximel fumarate

From WikiProjectMed
Jump to navigation Jump to search

Diroximel fumarate
Names
Trade namesVumerity
Other namesALKS-8700
Clinical data
Main usesRelapsing forms of multiple sclerosis (MS)[1]
Side effectsFlushing, abdominal pain, diarrhea, nausea[1]
Routes of
use		By mouth
External links
AHFS/Drugs.comMonograph
MedlinePlusa620002
Legal
License data
Legal status
Chemical and physical data
FormulaC11H13NO6
Molar mass255.226 g·mol−1
3D model (JSmol)
  • COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O
  • InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+
  • Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N

Diroximel fumarate, sold under the brand name Vumerity, is a medication used to treat relapsing forms of multiple sclerosis (MS).[1] This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] It is taken by mouth.[1]

Common side effects include flushing, abdominal pain, diarrhea, and nausea.[1] Other side effects may include anaphylaxis, progressive multifocal leukoencephalopathy, herpes zoster, liver problems, and low lymphocytes.[1] Use in pregnancy may harm the baby.[2] It works after the body converts it into monomethyl fumarate (MMF).[3]

Diroximel fumarate was approved for medical use in the United States in 2019.[3] While it was approved in Europe and the United Kingdom in 2021 it is not yet commercially available.[3] In the United States it costs about 7,900 USD per day as of 2021.[4]

Medical uses

It is used for the treatment of relapsing forms of multiple sclerosis (MS).[1][5][6]

Dosage

It is started at 231 mg twice per day for a week.[1] It is than taken as 462 mg twice per day.[1]

Society and culture

This drug was formulated by Alkermes in collaboration with Biogen.[7]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Vumerity- diroximel fumarate capsule". DailyMed. Archived from the original on 5 February 2021. Retrieved 1 February 2021.
  2. ↑ "Diroximel fumarate Pregnancy and Breastfeeding Warnings". Archived from the original on 14 February 2021. Retrieved 26 December 2021.
  3. ↑ 3.0 3.1 3.2 "Vumerity · Relapsing remitting multiple sclerosis (MS)". Archived from the original on 19 May 2021. Retrieved 26 December 2021.
  4. ↑ "Vumerity Prices, Coupons and Patient Assistance Programs". Retrieved 26 December 2021.
  5. ↑ Wang Y, Bhargava P (July 2020). "Diroximel fumarate to treat multiple sclerosis". Drugs of Today (Barcelona, Spain : 1998). 56 (7): 431–437. doi:10.1358/dot.2020.56.7.3151521. PMID 32648853.
  6. ↑ Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E (October 2020). "Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?". Pharmaceuticals (Basel, Switzerland). 13 (10): 306. doi:10.3390/ph13100306. PMC 7602023. PMID 33066228.
  7. ↑ "Archive copy". Archived from the original on 28 August 2021. Retrieved 30 July 2021.{{cite web}}: CS1 maint: archived copy as title (link)

External links

Identifiers:
  • "Diroximel fumarate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 28 August 2021. Retrieved 30 July 2021.
Stub icon

This pharmacology-related article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Diroximel_fumarate&oldid=1377254"